🌟 *Iovance (IOVA)* shares jump 19% after the FDA extended its target action date for its treatment for advanced melanoma, lifileucel, saying that there are no major review issues. Analysts said that, while the delay was disappointing, lack of an AdCom was a positive and approval is still on the cards.